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Objective: The aim of the present study was to determine the effect of an aggressive graft surveillance and endovascular
treatment protocol on secondary patency rates of a polyetherurethaneurea vascular access graft, specially designed to
provide early access and rapid hemostasis.
Methods: One hundred and ninety Vectra Vascular Access Grafts (C. R. Bard, Inc, Murray Hill, NJ) were placed in 176
patients (78 females and 98 males, mean age 61.7 years). There were 41 forearm grafts, 145 upper arm grafts and four
thigh grafts. Graft surveillance was performed by using clinical and hemodialysis parameters to detect a failing/failed
graft and followed by endovascular treatment, rheolytic thrombectomy (AngioJet, Possis Medical Inc, Minneapolis,
Minn) and/or angioplasty  stenting of the anatomical lesion (arterial anastomosis, graft, venous outflow, draining or
central veins).
Results:Hemodialysis started after a median of 15.5 days, as soon as from the day of the operation in some cases. Bleeding
complications occurred in six patients (3.2%), venous hypertension in seven (3.7%), steal syndrome in two (1.1%),
neurological complications in two (1.1%), while late infection (range 2.7-14.6 months) was seen in six patients (3.2%).
Thrombectomy and angioplasty (median number of sessions 1, interquartile range 1-2) was performed in 43 grafts.
Isolated angioplasty, not associated with thrombosis (median number of sessions 1, interquartile range 1-2), was
performed in 50 grafts. These interventions increased primary assisted patency from 69% and 63% at 12 and 18 months,
respectively to a secondary patency rate of 86%. Taking into account grafts removed for late infection, functional
secondary patency rate dropped to 83% and 81%, at 12 and 18 months, respectively. Arterial anastomosis angioplasty was
performed more frequently in thrombosed grafts (28.6%) than failing grafts (6.7%), P < .001 and had a significant
negative predictive value on secondary patency rates at 12 and 18 months, which were 60.5% compared with 89% for
grafts that had no interventions performed (P  .007) and 90.9% for grafts that had any intra-graft, venous outflow, or
draining or central vein stenosis treated with angioplasty at any stage (P  .002). Multivariate analysis identified the
presence of arterial anastomosis stenosis as the single predictor of secondary patency (relative risk 0.247, P  .002).
Conclusions: Aggressive graft surveillance and endovascular treatment increases significantly secondary patency rates of
Vectra Vascular Access Grafts. Longer follow-up will determine the effectiveness of this policy. The role of inflow stenosis
on graft longevity and alternative treatment options warrant further investigation. (J Vasc Surg 2007;45:974-80.)The development of the perfect vascular access graft is
beyond any doubt the holy grail of vascular access surgery.
With overall patency results being inferior to what achieved
with native fistulas, this is currently an illusive target; how-
ever, research performed the last decade has improved the
performance of hemodialysis grafts. Grafts that allow early
cannulation have been developed,1-5 without compromise
of their patency rates.4-5 Additional advances include rou-
tine graft surveillance using clinical and hemodynamic pa-
rameters,6 which became more widespread following the
recommendations of the National Kidney Foundation in
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9741997,7 which set targets for graft patency, in patients that
have exhausted autologous vein options.
The aim of the present study was to determine the
effect of an aggressive graft surveillance and endovascular
treatment protocol on secondary patency rates of a poly-
etherurethaneurea vascular access graft (Vectra Vascular
Access Graft, C. R. Bard, Inc, Murray Hill, NJ), specially
designed to provide early access and rapid hemostasis.
METHODS
During the 2-year period between March 2004 and
March 2006, 190 Vectra Vascular Access Grafts (C. R.
Bard, Inc, Murray Hill, NJ) were placed in 176 consecutive
patients, 78 females and 98 males, by a single attending
vascular surgeon (G.K.H.). Mean age was 61.7  14.9
years (range 21-89 years). Seventy-one patients had no
history of a previous graft or fistula and were not candidates
for creation of a primary native fistula, based on preopera-
tive imaging of their arm veins with venogram or ultra-
sound. The remainder had one or more access surgeries
performed and were not candidates for creation of a pri-
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same period of time, 305 fistulas were constructed. There
were 41 forearm grafts (loop configuration), 145 upper
arm grafts (straight configuration in all but two cases), and
four thigh grafts placed. Left arm was selected in the
majority of cases (n 126, 67.7%), the right one (n 60)
being a second choice when the left (nondominant side for
the majority of patients) arm and forearm had been used.
All grafts implanted were 5 or 6 mm in diameter.
In 174 grafts (91.6%), procedure was performed under
interscalene brachial plexus regional local anesthesia with
intravenous sedation. In 14 (7.4%) and 2 (1.1%) cases
anesthesia was general and spinal, respectively. Vectra Vas-
cular Access Graft is a tri-layered graft, composed of Tho-
ralon, a proprietary blend of segmented polyetherurethan-
eurea and a siloxane containing a surface-modifying
additive (SMA). Vectra has self-sealing properties allowing
early cannulation. The microporous outer layer is designed
to enhance graft anchoring and kink resistance, the solid
middle layer is responsible for the self-sealing graft proper-
ties, while the microporous blood-contacting inner layer
contains an SMA-rich environment designed to minimize
platelet adhesion. Manufacturer implantation guidelines
were followed to optimize graft placement, including pre-
vention of kinking. All anastomoses were performed with
6-0 polypropylene sutures (Prolene, Ethicon Inc, Somer-
ville, NJ).
Graft surveillance was performed by using clinical and
hemodialysis parameters to detect a failing/failed graft.
These included abnormal findings on clinical examination,
such as weak thrill or graft occlusion, ipsilateral arm edema
suggestive of a central venous stenosis, graft pain during
hemodialysis and prolonged bleeding time after hemodial-
ysis. Also identification of high venous pressures (300
mm Hg) or suboptimal blood flow (400 ml/min) or
recirculation while the patient receives hemodialysis.7 Fre-
quently, more than one criteria that are shown in Table I,
were present.
Endovascular treatment was subsequently performed
under local anesthesia with sedation as an outpatient pro-
cedure. Rheolytic thrombectomy using the AngioJet device
(Possis Medical Inc, Minneapolis, Minn) and a specially
Table I. This Table shows the graft surveillance criteria
(clinical and hemodialysis parameters) used in the current
study to detect a failing/failed graft
Clinical parameters
● Abnormal findings on clinical examination, such as weak thrill
or graft occlusion
● Ipsilateral arm edema suggestive of a central venous stenosis
● Graft pain during hemodialysis
● Prolonged bleeding time after hemodialysis
Hemodialysis parameters
● High venous pressures (300 mm Hg)
● Suboptimal blood flow (400 ml/min)
● Recirculation during hemodialysisdesigned catheter was performed for graft occlusion fol-lowed by angioplasty ( stenting) of the anatomical lesion
(arterial anastomosis, graft, venous outflow, draining or
central veins) responsible for the thrombotic event.8,9 Iso-
lated angioplasty ( stenting) of the anatomical lesion
(venous outflow, draining or central veins) was performed
for failing grafts,10 with an arterial anastomotic angioplasty
performed occasionally.11
Our technique is a modification of Beathard’s tech-
nique,12 and compromised by the following steps:
(1) Venous access: After local anesthesia is used, graft is
cannulated about 3-5 cm from the arterial anastomo-
sis, with an 18 gauze access needle (CookMedical Inc,
Bloomington, Ind) pointing toward the venous anas-
tomosis. A 0.035-inch hydrophilic wire is passed under
fluoroscopy up to the central veins if possible. C-arm
devices used were the OEC Series 9600 (OECMedical
Systems Inc, Salt Lake City, Utah) and more recently
the BV Pulsera (Philips Medical Systems, Nederland,
BV). Then a 6 Fr introducer sheath is inserted. Com-
pletion of wire advance to the central veins is then
performed with the aid of a 5 Fr guiding catheter if
necessary. Initial angiogram of the draining and central
veins is optional at this stage, we usually perform this
during step 3.
(2) Arterial access and embolectomy: A second graft can-
nulation under local anesthesia 3-5 cm away from the
venous anastomosis is performed, with the 18 gauze
access needle pointing toward the arterial anastomosis.
A 0.025 inch hydrophilic wire is passed under fluoros-
copy down to the radial artery. Once crossing of both
anastomoses is achieved, 70 iu/Kg of unfractionated
heparin sodium is administered intravenously; heparin
is not given earlier in case of failure of crossing the
anastomoses, which precludes thrombectomy and
mandates placement of a tunneled central vein cathe-
ter. Then arterial embolectomy to remove the so called
“white” plug is performed with an over-the-wire 4 Fr
Fogarty thru-lumen embolectomy catheter (Edwards
Lifesciences, Irvine, Calif) inflated with 50% contrast
solution and under fluoroscopy.
(3) Mechanical thrombolysis of the venous side: An over-
the-wire AVX AngioJet catheter (Possis Medical, Inc,
Minneapolis, Minn) is introduced over the wire and
parked under fluoroscopy (using the radiopaque cath-
eter marker bands) distal to the anastomosis. Catheter
is then activated and thrombolysis begins by pulling it
back. Then an angiogram is performed and if no flow
recovery is achieved, thrombolysis procedure is re-
peated.
(4) Angioplasty (arterial and/or venous): Angioplasty of the
stenotic lesion (arterial anastomosis, graft, venous out-
flow, draining or central veins) using standard techniques
(Fig 1). Sometimes multiple angioplasties are performed.
In case of residual stenosis, more than 20% cutting bal-
loon (Boston Scientific Corporation, Natick, Mass) or
high pressure balloon (C. R. Bard, Inc, Murray Hill, NJ)
is used; if these fail, stenting is performed using self
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Co, Miami Lakes, Fla and LUMINEXX Stent, C. R.
Bard, Inc, Murray Hill, NJ). Graft stenoses resistant to
balloon angioplasty (and two incidental graft pseudoan-
eurysms) were managed with Fluency stent-grafts (C. R.
Bard, Inc, Murray Hill, NJ).
(5) Completion angiogram: This is done to confirm graft
flow and that stenotic areas are patent.
(6) Hemostasis: A figure of eight 3-0 Ethilon (Johnson &
Johnson, New Brunswick, NJ) is placed at each cannu-
lation site. Sites are covered with a Band-Aid.
After successful thrombolysis, graft can be immediately
used for hemodialysis.
All patients were followed up to the end of secondary
patency (final thrombotic event), graft removal (because of
infection), or death. The study was approved by the hospi-
tal institutional review board.
Statistics. All data were entered into a Microsoft Office
Excel database (Microsoft Inc, Redmond, Wash) and ana-
lyzed with SPSS 14.0 for Windows (SPSS Inc, Chicago, Ill).
Reporting Standards for Arterio-Venous Accesses of the Soci-ety for Vascular Surgery and the American Association for
Vascular Surgery were used to define graft patency.13
Primary assisted patency was defined as patent graft
without thrombectomy. Secondary patency was defined as
grafts that were patent after thrombectomy, the terminal
thrombotic event being taken into account to estimate
secondary graft patency rates. Functional secondary graft
patency was defined as above but also took into account
grafts removed for late infection. Graft patency rates were
calculated with the Kaplan-Meier method and compared
with the log-rank (Mantel-Cox) test. Multivariate analysis
of the effect of clinical parameters on patency rates was
performed with the Cox regression method (Forward and
Backward Wald models). Categorical data were analyzed
with the 2 or Fisher exact test where appropriate.
RESULTS
Hemodialysis started after a median of 15.5 days (in-
terquartile range 9-28.7 days, range 0-154 days), as soon as
from the day of the operation in five patients and day one in
Fig 1. Effect of balloon angioplasty on a venous outflow steno-
sis. A, Pre-angioplasty angiogram. B, Angioplasty with balloon.
C, Post-angioplasty angiogram, showing resolution of the steno-
sis.12 additional patients. Central catheter was usually re-
bclavi
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operative bleeding complications occurred in six patients
(3.2%), venous hypertension (hand/arm edema) in seven
(3.7%), steal syndrome in two (1.1%), neurological compli-
cations (ischemic monomelic neuropathy and carpal tunnel
syndrome) in two (1.1%). There was no instance of graft
seroma. Postoperative complications occurred more fre-
quently in forearm grafts (19.5%) than upper arm grafts
(6.2%), P  .015 (Fisher exact test). Late graft infection
(range 2.7-14.6 months) was seen in six patients (3.2%).
Isolated angioplasty, not associated with thrombosis
(median number of sessions 1, interquartile range 1-2), was
performed in 50 grafts. Thrombectomy and angioplasty
(median number of sessions 1, interquartile range 1-2) was
performed in 43 grafts. Table II shows the distribution of
angioplasty and stenting procedures performed for the
endovascular management of failed (thrombosed) and fail-
ing Vectra grafts. Arterial anastomosis angioplasty was per-
formed more frequently in thrombosed grafts (28.6%) than
failing grafts (6.7%), P  .001. Stenting followed a similar
pattern.
These interventions increased primary assisted patency
rate from 92%, 69%, and 63% at 1, 12, and 18 months,
respectively to a secondary patency rate of 97%, 86%, and
86% at 1, 12, and 18 months, respectively (Fig 2). Taking
into account grafts removed for late infection, functional
secondary patency rate dropped to 83% and 81%, at 12 and
18 months, respectively.
Presence of arterial anastomotic stenosis treated with
angioplasty at any stage had a significant negative predictive
value on secondary patency rates at 12 and 18 months,
which were 60.5% compared with 89% for grafts that had
no interventions performed (P .007) and 90.9% for grafts
that had any intra-graft, venous outflow, or draining or
central vein stenoses treated with angioplasty at any stage
(P  .002), Fig 3. Presence of individual graft, venous
outflow, or draining or central vein stenoses treated with
angioplasty did not have any negative effect on secondary
Table II. This Table shows the distribution of angioplasty
isolated angioplasty or failed (thrombosed) grafts that und
Arterial angioplasty was performed more frequently in thro





Failing grafts (n  50,
75 sessions) 5 (6.7) 29 (37.7) 67
Failed grafts (n  43,
77 sessions) 22 (28.6) 32 (42.7) 61
P value .001 .529
Odds ratio (95% CI) 5.6 (2.0-15.7) 0.81 (0.42-1.55) 0.46
All sessions (n  152) 27 61
*for subclavian and graft stenosis. Two additional stent-grafts were placed f
#for venous outflow (n  8), arterial stenosis (n  2), graft (n  1), and supatency rates (P  .05). Presence of stenosis that necessi-tated stenting had a marginally significant negative predic-
tive impact on secondary patency rates at 12 and 18
months, which were 62.2% compared with 87.3% for pa-
tients that had no stent inserted (P  .067).
Age, gender, history of previous vascular access pro-
cedures, graft site, and side had no effect on primary
assisted or secondary patency rates (P  .05), although
there was a trend towards better primary assisted patency
in males (74% and 67% at 12 and 18 months, respec-
tively, compared with 64% and 56% for females, P  .06,
Fig 4) and secondary patency for upper arm grafts (87%
at 12 and 18 months compared with 78% for forearm
grafts, P  .09). Multivariate analysis identified the
presence of arterial anastomosis stenosis as the single
predictor of secondary patency (Beta  -1.4, SE  .448,
Wald  9.78, P  .002, exp(B) (relative risk)  0.247,
95.0% confidence interval 0.102-0.593). Patient survival
stenting procedures in failing grafts that underwent
nt thrombectomy and ancillary endovascular procedures.
sed (failed) grafts (28.6%) than failing grafts (6.7%), P 
ern.
edures [n (%)]
Stenting [n (%)]tflow Draining veins Central veins
) 32 (42.7) 14 (18.7) 2 (2.7)*
) 41 (53.2) 12 (15.6) 13 (16.9)#
.192 .614 .003
-1.14) 1.53 (0.81-2.90) 0.80 (0.35-1.88) 7.4 (1.61-34.10)
73 26 15
ft pseudoaneurysms.
an stenosis (n  1).
Fig 2. This figure shows the effect of mechanical thrombectomy
and subsequent graft surveillance with indicated secondary inter-
ventions on patency rates of the Vectra graft. These interventions
increased primary assisted patency from 69% and 63% at 12 and 18
months respectively to a secondary patency rate of 86% that was
sustained up to 2 years. Error bars of the survival curves represent












or grarate at 18 months was 85%.
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The present study showed that aggressive graft surveil-
lance and endovascular treatment increase significantly the
secondary patency rates of Vectra Vascular Access Grafts,
which are specially designed to be used as soon as the first
postoperative day. Early graft cannulation was possible for
majority of the grafts, although median time to hemodial-
ysis in our patients (15 days); a wide range of median or
mean time to hemodialysis has been reported,4,5,14-16 in
two of these studies this time was 19 and 20 days, respec-
tively.4-16 The majority of the patients in our study had
elective placement of their access graft and, therefore, an
alternative access mode (tunneled or non-tunneled cathe-
Fig 3. This figure demonstrates the negative predictive value of
arterial anastomotic stenosis detected and treated with angioplasty
at any stage during graft’s life on secondary patency rates, which
were 60.5% at 12 and 18 months compared with 89% for patients
that had no interventions performed (P  .007) and 90.9% for
patients that had any graft, venous outflow, or draining or central
vein stenoses treated with angioplasty at any stage (P  .002).
Error bars of the survival curves represent standard error, while the
number of patients at risk at each interval is also shown.
Fig 4. This figure shows the effect of gender on primary assisted
patency rates of the Vectra graft. Grafts in males had a slightly
better patency, 74% and 67% at 12 and 18 months, respectively,
compared with 64% and 56% in females, P .06. Error bars of the
survival curves represent standard error, while the number of
patients at risk at each interval is also shown.ter) was available and used until complete wound healing.Also some patients received their graft in anticipation of
deterioration of their renal function and thus hemodialysis
was deferred until this happened. Nevertheless, our results
compare favorably with those achieved using PTFE grafts
that are not generally used the first 2 weeks after surgery.4
Postoperative complications were rare and occurred
more frequently in forearm grafts than upper arm grafts, a
finding consistent with a previous report.17 No seroma
formation was seen in this series, a complication seen in
PTFE grafts.18,19 This is probably the effect of the self-
sealing graft properties of the solid middle graft layer and
research towards grafts with minimal porosity is ongoing.18
The role of graft surveillance is controversial, although
recommended by most experts to increase primary patency
rates.6,7,10,20-22 A variety of hemodynamic criteria has been
suggested; we used multiple clinical and hemodynamic
criteria and had a low threshold of performing diagnostic
graft angiogram in order to increase sensitivity and achieve
high primary assisted and secondary patency rates. The
Kidney Disease Outcomes Quality Initiative guidelines of
the National Kidney Foundation suggest routine patient
monitoring and graft surveillance for the early detection of
failing access fistulae and grafts. The same guidelines ac-
knowledge the fact that appropriate intervention with per-
cutaneous transluminal angioplasty or surgical revision to
correct stenoses dramatically reduces the rate of AV graft
thrombosis and loss.23 Clinical trial results support this
recommendation.24-26
Once grafts got thrombosed we used mechanical
(rheolytic) thrombolysis. Our experience was that it is safe
as previously reported.12 Rare complications like pulmo-
nary embolism,27 arterial embolism,12,28,29 or paradoxical
brain embolism,30,31 were not encountered.
The high yield of mainly outflow stenoses, around 90%,
is consistent with a previous study.12 In contrast, we found
a high incidence of arterial stenoses; these have been re-
cently recognized as being more frequent than previously
thought;11,32,33 our study expands our understanding on
the inflow factor based on the higher incidence of inflow
stenosis in thrombosed grafts and its prognostic role. Al-
ternative treatment modalities, like routine stenting and
perhaps close follow-up monitoring of arterial inflow ste-
noses might be indicated based on the significantly lower
secondary patency rate that they are associated with.
Being minimally invasive, thrombectomy methods are
usually able to restore access patency and can be repeated
several times before surgical revision becomes manda-
tory.34 The inability of endovascular procedures to main-
tain all grafts patent might be the result of a hypercoagula-
ble disorder as previously suggested,35 and might explain
the failure of technical modifications.36,37
Primary assisted and secondary patency rates reported
by the current study compared favorably with what re-
ported by previous studies tested the Vectra graft. We
attribute this finding to our aggressive policy in surveillance
and good results of endovascular maintenance; these inter-
ventions improved significantly secondary patency rates.
Mean primary and secondary patency at 1 year of the seven
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respectively,4,5,14-16,38,39 compared with 69% and 86%
shown by our study. Unfortunately, the authors of these
studies provided little information about surveillance and
endovascular treatment procedures. Our study is also
unique in the sense that we reported functional secondary
patency rates (total usage rates), taking into account grafts
removed for late sepsis. Peng reported a 1-year functional
secondary patency rate of 64%.16
A trend towards better primary assisted but not second-
ary patency was observed in males (P .06); this might be
related to anatomical reasons since women have smaller size
arteries. A previous study showed that female gender was
not significantly associated with failure of synthetic grafts.40
Age, gender, history of previous vascular access procedures
and side had no effect on patency rates. Our study showed
that secondary patency for upper arm grafts was marginally
worse compared with forearm grafts. Previous studies have
shown conflicting results. Upper arm grafts have better
patency40 and so is the case for straight grafts.20 Kola-
kowski reported that primary, but not secondary, patency
was worse in forearm grafts,17 but Savader demonstrated
the opposite pattern.41 Vectra grafts have a tendency to
kink and therefore looped configuration makes them po-
tentially vulnerable.20 Special implantation guidelines ad-
dress this potential issue.
In conclusion, aggressive graft surveillance and endo-
vascular treatment increases significantly secondary patency
rates of Vectra Vascular Access Grafts. Excellent results
were maintained at 18 months, while longer follow-up will
determine the effectiveness of this policy. The role of inflow
stenosis on graft longevity and alternative treatment op-
tions warrant further investigation.
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